Aurobindo Pharma, an Indian private pharmaceutical company, informed that it has got tentative sanction from US Food & Drug Administration (USFDA) to make and sell fixed dosed combination Abacavir Sulfate/ Lamivudine Tablets.

The company has been allowed to manufacture the drugs in the strengths of 60/30 mg.

Abacavir sulfate tablets are indicated for the treatment of HIV infection in adults and children 3 months of age or older.

On the other hand, Lamivudine tablets are recommended to the treatment of chronic hepatitis B, at a lower dose needed for the treatment of HIV.

According to sources, Aurobindo had earlier received sanction to co-packaged Lamivudine/ Zidovudine tablets + Abacavir Sulfate tablets in the strengths of 150/300 mg + 300 mg and Abacavir Sulfate / Lamivudine tablets 600/300 mg.